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Abstract
Inositol hexaphosphate (IP6) is a major constituent of most cereals, legumes, nuts, oil seeds and soybean. Previous studies reported the anticancer
effect of IP6 and suggested that co-treatment of IP6 with inositol may enhance anticancer effect of IP6. Although the anticancer effect of IP6 has
been intensively studied, the combinational effect of IP6 and inositol and involved mechanisms are not well understood so far. In the present study,
we investigated the effect of IP6 and myo-inositol (MI) on cell cycle regulation and apoptosis using PC3 prostate cancer cell lines. When cells
were co-treated with IP6  and  MI, the extent of cell growth inhibition was significantly increased than that by IP6 alone. To identify the effect 
of IP6 and MI on apoptosis, the activity of caspase-3 was measured. The caspase-3 activity was significantly increased when cells were treated
with either IP6 alone or both IP6 and MI, with no significant enhancement by co-treatment. To investigate the effect of IP6 and MI of cell cycle
arrest, we measured p21 mRNA expression in PC3 cells and observed significant increase in p21 mRNA by IP6. But synergistic regulation by 
co-treatment with IP6 and MI was not observed. In addition, there was no significant effect by co-treatment compared to IP6 treatment on the regulation
of cell cycle progression although IP6 significantly changed cell cycle distribution in the presence of MI or not. Therefore, these findings support 
that IP6 has anticancer function by induction of apoptosis and regulation of cell cycle. However, synergistic effect by MI on cell cycle regulation 
and apoptosis was not observed in PC3 prostate cancer cells.
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Introduction6)
Inositol hexaphosphate (IP6), which is also known as phytic 
acid, is a major constituent of most cereals, legumes, nuts and 
soybean. In plants, phytic acid exists as salt with monovalent 
and divalent cations (Shamsuddin et al., 1997). IP6 and lower 
phosphorylated inositols (IP1-5) are also found in almost all 
mammalian cells in substantial amounts up to 1 mM (Sasakawa 
et al., 1995; Shamsuddin, 1999). The second messenger role of 
inositol 1,4,5-trisphosphate (IP3) in bringing about a host of 
cellular functions including mitosis via mobilizing intracellular 
Ca
2+  is well recognized. Inositol 1,3,4,5-tetraphosphate (IP4) and 
inositol 1,3,4,5,6-pentaphosphate (IP5) have been shown to 
induce Ca
2+ sequestration (Shamsuddin et al., 1997). Recently, 
many studies have shown several health benefits of IP6  and 
anticancer efficacy of IP6 has been observed both in vivo and 
in vitro studies (Vucenik & Shamsuddin, 2003). IP6 inhibited 
tumor growth by induction of apoptotic cell death, cell cycle 
arrest and differentiation of several human cancer cell lines 
including colon (Sakamoto et al., 1993), liver (Vucenik et al., 
1998a), prostate (Singh et al., 2003; Zi et al., 2000) and breast 
(Shamsuddin et al., 1996; Vucenik et al., 2005). Also, the ability 
of IP6 to reduce the incidence and multiplicity of mammary 
tumors has been demonstrated in a variety of animal models 
including chemical-induced (Estensen & Wattenberg, 1993; Vu-
cenik et al., 1995) and transplanted tumor model (Singh et al., 
2004; Vucenik et al., 1998b). 
Inositol phosphates are synthesized from the parent molecule 
inositol, and it is estimated that adults consume approximately 
1g of inositol per day (Shamsuddin et al., 1997). Myo-inositol 
(MI) is a parent compound of IP6 and has been found in plants 
(Reddy et al., 1982). The addition of inositol, a precursor of 
inositol phosphates, to IP6 have been shown to enhance the 
anticancer function of IP6  in vivo (Shamsuddin et al., 1989; 
Vucenik et al., 1995). The synergistic effect may be by which 
IP6 plus inositol exerts their action via lower-phosphate inositol 
phosphates, which serve as intracellular second messengers. Mea-
surement of intracellular inositol phosphates after IP6 treatment 
showed inconsistent change regarding lower-phosphate inositol 
phosphates. When rats were fed AIN-76A + 1% IP6 diet for 12 
weeks, there were no significant changes in the IP3 contents 
depending on IP6 ingestion in food, while the levels of IP6 in 
both brain and plasma were very sensitive to its presence in the 
diet (Grases et al., 2002). However, in human malignant cell 
lines following IP6 treatment, the increases in intracellular levels 
of IP3 or other lower phosphorylated inositols have suggested 
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the important role of these metabolites as mediators of anti-cancer 
action of IP6 (Ferry et al., 2002; Grases et al., 2002). In fact, 
cell proliferation was inhibited by inositol 1,3,4,5,6-pentapho-
sphate and inositol 1,4,5,6-tetraphosphate at micromolar concen-
trations in various cancer cells (Ferry et al., 2002; Razzini et 
al., 2000). 
Although several studies using animal models showed the 
synergistic effect of IP6 and inositol, the synergistic effect and 
involved mechanism are far for being understood in cancer cell 
lines. Therefore, in the present study, we treated PC3 cell lines 
with IP6 and MI to investigate the synergistic effect along with 
the involved molecular mechanism.
Materials and Methods
Cell culture and treatment
The androgen-independent human prostate cancer cell line PC3 
was obtained from the KCLB (Seoul, Korea). Cells were cultured 
in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (Cambrex, USA), 100 units/ml penicillin, and 100 µg/ml 
streptomycin at 37℃ in a humidified 5% CO2  incubator (Sanyo, 
Japan). Cells were cultured for 24 h after plating and treated 
with IP6 (0.5, 1 mM) and/or MI (5, 10 mM) dissolved in complete 
culture medium for 48 h. IP6 and MI were purchased from 
Sigma-Aldrich (USA).
Determination of cell growth
After treatment, cells were washed with PBS and collected by 
a brief trypsinization, stained with 0.4% trypan blue (Invitrogen, 
USA), and unstained cells were counted in duplicate with a 
hemacytometer. The effect of each treatment on growth inhibition 
was assessed as the percentage of inhibition in cell growth where 
control cells were taken as 100% viable.
Cell cycle phase distribution by flow cytometry
The effect of IP6 on cell cycle phase distribution was assessed 
using flow cytometry. Briefly, after treatment of cells, floating 
cells were collected and the attached cells were trypsinized and 
washed twice with cold PBS. Thereafter, floating cells were 
combined with washed attached cells and total cells were 
centrifuged at 100 g for 5 min, pellet was resuspended in PBS 
containing albumin. Resuspended cells were mixed in 70% EtOH 
and stored at -20℃  until analysis. For analysis, cells were 
centrifuged and resuspended in PBS with RNAase at 37℃ for 
30 min. The cells were then chilled over ice for 10 min and 
stained with propidium iodide (50 µg/ml final concentration) for 
1 h for analysis by flow cytometry. Flow cytometry was 
performed with a FACScan (Becton Dickinson, Germany). 
Measurement of mRNA levels by semiquantitative RT-PCR
Total RNA was isolated from the cells using Trizol (Invitrogen, 
USA) and RNA concentration was measured spectrometrically 
at 260 nm. The quality of RNA was also determined by running 
MOPS-RNA gel and the integrity of two bands was assured. Total 
cellular RNA was isolated using Trizol Reagent (Invitrogen, 
USA) and cDNA was synthesized using 2 µg of total RNA with 
the Superscript
TM First-strand synthesis system (Invitrogen, 
USA). For amplification of cDNA, primers for p21 (upstream 
primer, GACAGCAGAGGAAGACCAT; downstream primer, 
TGGAGTGGTAGAAATCTGTCAT; 55℃) were used. Expre-
ssion of β-actin was examined as an internal control (upstream 
primer, GTTTGAGACCTTCAACACCCC; downstream primer, 
GTGGCCATCTCCTGCTCGAAGTC; 60℃). For each combi-
nation of primers, the kinetics of PCR amplification was studied, 
the number of cycles corresponding to plateau was determined, 
and PCR was performed within the exponential range. Amplified 
products were separated on an agarose gel and visualized with 
ethidium bromide staining. The results were quantitated using 
Fluor-S
TM MultiImager (Bio-Rad, USA).
Determination of caspase-3 activities 
The activity of caspase-3 was measured by Caspase-3 color-
imetric assay kit (MBL, USA). Briefly, after treatment, cells were 
collected and lysed. One hundred micrograms of cell lysates were 
loaded into 96-well microplates, and mixed with reaction buffer 
and substrate for 2 h in an incubator at 37℃. Absorbance was 
measured using a multiwell reader (Bio-Rad, USA) at 405 nm 
every 30 min to confirm the linearity of absorbance. Protein 
content was determined using the Bio-Rad protein assay reagent 
(Bio-Rad, USA). Caspase-3 activity was first expressed as change 
in absorbance units per microgram protein and per hour and then 
converted to the relative value compared to control. 
Statistical methods
The data were analyzed using SAS software. For all exper-
iments, one-way ANOVA followed by Duncan's multiple range 
test was employed to asses the statistical significance. Data were 
expressed as mean ± SEM and statistical significant difference 
was considered to be present at p<0.05.
Results
PC3 cells were cultured for 24 h after plating and various 
concentrations of IP6 and MI were added to the well, followed 
by further incubation for 48 h. Viable cell numbers were counted 
manually by hemocytometer after trypan blue staining. As shown 
in Fig. 1, IP 6 treatment inhibited the growth of human prostate 
carcinoma PC3 cells in a dose-dependent manner. Treatment of Hyun-Jung Kim et al. 197
Fig. 1. Effects of IP6 and MI on inhibition of PC3 cell growth. Twenty-four hours 
after plating, cells were treated with IP6, MI, or IP6 plus MI at concentrations as 
described for 48 h. After treatment, cells were harvested and cell numbers were 
estimated  by  trypan  blue  exclusion  method.  Each  bar  represents  mean ± SEM 
(n=3)  and  bars  with  different  superscripts  are  significantly  different  at  p＜0.05.
Fig. 2. Effects of of IP6 and MI on apoptosis of PC3 cells. Twenty-four hours 
after plating, cells were treated with IP6, MI, or IP6  plus MI at concentrations as 
described for 48 h. Caspase-3 activity was measured using colorimetric assay kit 
and the resulting data is expressed as percentage of the control value. Each bar 
represents mean ± SEM (n=3) and bars with different superscripts are significantly 
different  at  p＜0.05.
 (A)
Fig. 3. Effects of IP6 and MI on the p21 mRNA expression. Twenty-four hours 
after plating, cells were treated with IP6, MI, or IP6  plus MI at concentrations as 
described for 48 h. (A) Representative photographs of 3 independent experiments 
are shown. (B) The relative abundance of p21 was quantified with the control level 
set  at  100%.  Each  bar  represents  mean ± SEM  (n=3)  and  bars  with  different 
superscripts  are  significantly  different  at  p＜0.05.
Table 1. Effects of IP6 and MI on PC3 cell cycle distribution
Treatment
% Cells
Sub G0/G1 G0/G1 S G2/M
Control 1.65 ± 0.17
c 49.70 ± 0.98
a 15.44 ± 0.51
a 29.11 ± 0.81
b
0.5 mM IP6 4.68 ± 0.23
b 47.75 ± 1.27
a 13.24 ± 0.33
b 29.61 ± 0.97
ab
1 mM IP6 8.43 ± 0.79
a 43.89 ± 0.85
b 11.82 ± 0.54
bc 31.23 ± 0.71
ab
5 mM MI 1.72 ± 0.31
c 48.39 ± 1.31
a 14.90 ± 0.86
a 30.51 ± 0.82
ab
0.5 mM IP6+5  m M  M I 5.06±0.50
b 48.64 ± 1.46
a 12.29 ± 0.37
bc 29.45 ± 0.99
b
1 mM IP6 + 5 mM MI 8.53 ±1.53
a 42.94 ± 1.22
b 11.11 ± 0.59
c 33.17 ± 2.01
a
Cells were treated with various concentrations of IP6 or MI for 48 h. Both floating 
and attached cells were collected and processed for analysis of cell cycle distribution 
by flow cytometry following staining with propidium iodide. Data are means ± SEM 
(n=5).  Means  with  different  superscripts  are  significantly  different  at  p＜0.05  by 
Duncan's  multiple  range  test. 
cells with 10 mM MI significantly affected on cell number, but 
no significant effect on cell growth was observed by 5 mM MI. 
When cells were co-treated with IP6 and MI, cell growth was 
significantly decreased compared to those in cells treated with 
either IP6 or MI. However, additional inhibitory effect by 
different concentrations of MI treatment was not observed.
To determine the involved mechanism regarding decreased 
number of cells, we investigated apoptotic effect by IP6 and/or 
MI by measurement of caspase-3 activity. As shown in Fig. 2, 
1 mM IP6 only and 1 mM IP6 plus 5 mM MI treatments 
significantly increased the activity of caspase-3, suggesting the 
possible involvement of caspase activation as one of the possible 
mechanisms of apoptosis induction. However, we could not 
observe apoptotic effect by MI alone. In addition, synergistic 
effect by IP6 and MI co-treatment on caspase-3 activity was not 
observed.
We measured p21 mRNA expression to investigate the 
involvement of cell cycle arrest in the inhibition of cell growth 
by IP6 and MI co-treatment. Eukaryotic cell cycle progression 
is regulated by sequential activation of various CDKs, which 
activities are dependent on their association with corresponding 
cyclins and cyclin-dependent kinase inhibitors (CDKI) (Morgan, 
1995). As shown in Fig. 3, there was an upregulation of p21 
mRNA level after IP6, which is consistent with the previous study 
using LNCaP cells (Agarwal et al., 2004). However, there was 
no significant difference in p21 mRNA level between IP6 
treatment only and IP6 and MI co-treatment. 
Because cell cycle progression is an essential event for cellular 
growth, we also examined whether the cell growth inhibitory 
effect by IP6 and/or MI is mediated through an alteration in a 
specific phase of the cell cycle progression. For this experiment, 
flow cytometric analysis of cells (both attached and floating cells) 
was conducted after staining cells with propidium iodide. Table 
1 summarized the effect of IP6 and/or MI treatment on the cell 
cycle distribution of PC3 cells. Treatment of cells with 1 mM 
IP6 significantly changed cell cycle phase distribution compared 198 No effect of MI on apoptosis of PC3 cells
to that of control group by increasing cells in sub G0/G1 and 
by decreasing cells in G0/G1 and S phases. Although we also 
observed significant changes in cell cycle distribution by 
co-treatment with 1 mM IP6 and 5 mM inositol, there was no 
significant difference in cell cycle phase distribution between IP6 
treatment only and IP6 and MI co-treatment.
Discussion
Although the anticancer effect of IP6 has been intensively 
studied, the combinational effect of IP6 and inositol and the 
involved mechanisms are not well understood so far. Therefore, 
we investigated the effect of co-treatment of IP6 and MI, which 
are easily consumed by the same diet such as soy, on apoptotic 
cell death and cell cycle regulation of prostate cancer cell PC3.
In the present study, we could not observe the significant 
anticancer effect of inositol on prostate cancer cell line. Although 
its effect was shown in some in vivo studies, its efficacy was 
different depending on the type of cancer (Estensen & Wat-
tenberg, 1993; Vucenik et al., 1995). Also, there has been no 
previous study investigating the effect of inositol on prostate 
cancer cell lines. In addition, we could not observe the synergistic 
effect of IP6 and inositol on apoptosis of PC3 cells. Several 
studies proposed the underlying mechanism of synergistic 
inhibition of cell proliferation as the increased synthesis of low 
number of IPs by stimulating dephosphorylation of IP6. When 
HeLa cells were treated with [
3H]IP6, the inhibition of cell growth 
was observed with increased synthesis of [
3H]IP4 and [
3H]IP5 
(Ferry et al., 2002). In addition, when small cell lung cancer 
(SCLC) cells were treated with either IP4 or IP5,  the cell growth 
was significantly decreased compared to that of cells treated with 
either  IP3  or IP6  (Razzini et al., 2000). Therefore, further studies 
will be needed in the aspect of the synthesis of low number 
of IPs from co-treatment of IP6 and inositol. 
Our data showed that caspase-3 activity was significantly 
increased when cells were treated with IP6, which is consistent 
with previous studies using HeLa cells (Ferry et al., 2002) and 
PC3 cells (Diallo et al., 2006). These consistent increases in 
caspase-3 activity by IP6 suggest that caspase activation might 
be the main mechanism of IP6-induced apoptosis in PC3 cells. 
The apoptotic effect by IP6 and/or MI is also consistent with 
FACS data, which also showed the significant increase in subG0 
phase when cells were treated with either IP6 alone or IP6 and 
MI together. 
Cell cycle arrest in either G1 phase or G2/M phase has been 
demonstrated as one of anticancer mechanism. Accordingly, we 
assessed the level of p21 mRNA and showed the significant 
change by combined treatments of IP6 and/or MI. As PC3 is 
a p53-negative cell line (Isaacs et al., 1991) unlike LNCaP cells, 
these modulations of proapoptotic proteins and induction of 
apoptosis were independent of p53. The previous study showed 
that IP6 (0.25-4 mM) induced G1 arrest, and, in time kinetics, 
maximum G1 arrest at 24 h of treatment, which was sustained 
significantly up to 72 h in DU145 cells (p53
mt/mt) (Singh et al., 
2003). However, the G1 arrest was not observed in our study 
when cells were treated with IP6, which could be due to the 
use of different types of cancer cell lines. Although cell doubling 
time of PC3 and DU145 is shown about 40 h without significant 
difference between two cell lines (Diallo et al., 2006), the 
previous study showed different patterns of cell cycle alteration 
by the addition of selenium (Venkateswaran et al., 2002). In 
addition, PC3 cells are androgen-insensitive cells. A recent study 
showed that prostate cancer cells that did not express the 
androgen receptor were more sensitive to the effects of IP6 on 
cellular metabolism as well as apoptosis (Diallo et al., 2006). 
Therefore, the molecular mechanism of IP6 may be different in 
cancer cells representative of different malignancy grades and 
these differences might be explained by the distinct profile of 
steroid receptors present in various cell lines.
Taken together, the data presented in this work indicate that 
IP6 induces caspase-3-mediated apoptosis and p21-mediated cell 
cycle regulation. Although we observed synergistic inhibition of 
cell growth by IP6 and MI co-treatment, we could not observe 
differences in the regulation of cell cycle phase distribution as 
well as apoptosis by the addition of MI to IP6. Therefore, further 
studies regarding inhibitory effect by IP6 and MI co-treatment 
on tumor cell differentiation and tumor marker expression need 
to be investigated. 
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